Cigna earnings beat by $0.04, revenue topped estimates
Beyond Meat Inc . (NASDAQ:BYND) stock has tumbled to a 52-week low, reaching a price level of just $2.5, with a market capitalization now at $193 million. According to InvestingPro analysis, the company’s financial health score stands at a concerning 1.09, labeled as "WEAK." This latest dip reflects a significant downturn for the plant-based meat substitute company, which has seen its shares plummet by 62.35% over the past year. Investors have been digesting a mix of industry headwinds and competitive pressures that have weighed heavily on the company’s financial performance and stock valuation. With a significant debt burden of $1.2 billion and negative EBITDA of -$125.5 million, the company faces substantial challenges ahead of its upcoming earnings report on May 7. The stark 52-week low serves as a stark indicator of the market’s recalibrated expectations for Beyond Meat’s growth prospects in an increasingly crowded and challenging sector. Get deeper insights into BYND’s financial health metrics and access the comprehensive Pro Research Report, along with 15+ additional ProTips, available exclusively on InvestingPro.
In other recent news, Beyond Meat Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $76.7 million, which slightly exceeded expectations. However, the company missed its earnings per share (EPS) forecast, reporting a loss of -0.65 compared to the anticipated -0.44. The earnings report also highlighted a positive gross margin of 13.1%, a significant improvement from the previous year’s negative margin. Beyond Meat’s management has set a revenue guidance for 2025 between $320 million and $335 million, with a target gross margin of approximately 20%.
Jefferies analysts revised their outlook on Beyond Meat, lowering the price target to $3.15, while maintaining a Hold rating. They noted that the company’s liquidity issues remain a significant challenge. Meanwhile, TD Cowen analysts reduced their price target to $2.50 and maintained a Sell rating, citing a shortfall in gross profit and EBITDA. Mizuho (NYSE:MFG) Securities reiterated an Underperform rating with a price target of $3.00, expressing skepticism about the company’s ability to achieve positive EBITDA by the end of 2026.
BMO Capital Markets also adjusted its outlook, reducing the price target from $6.00 to $5.00 while maintaining a Market Perform rating. The firm acknowledged Beyond Meat’s efforts in cost optimization but expressed concerns about the sales trajectory. Beyond Meat plans to achieve positive EBITDA by the end of 2026, with measures including workforce reductions and suspension of operations in China.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.